US-China Trade Talks Sideline Chip Export Controls as Nvidia China Sales Draw Attention 
Amazon Faces Class-Action Lawsuit Over Trump Tariff Price Hikes 
Samsung Union Talks Enter Final Stage as Strike Threat Looms 
Samsung Shares Drop as Labor Union Confirms Planned Strike 
Berkshire Hathaway Reveals New Stakes in Delta Air Lines and Macy’s Under Greg Abel 
Sonova Beats Profit Forecasts Despite Cochlear Implant Weakness 
Alibaba Stock Surges After Strong Q4 Earnings Boosted by AI and Cloud Growth 
Nvidia’s China AI Chip Sales Remain Frozen Despite U.S. Approval 
Honda Shares Jump as Automaker Forecasts Profit Recovery Despite Historic Loss 
SoftBank Shares Slide Despite Record Q4 Profit Fueled by OpenAI Investment 
Telefónica Q1 2026 Earnings Beat Expectations as Debt Declines and Cash Flow Improves 
Elliott Targets Bio-Rad as Shares Continue to Struggle 
Asia-Pacific Banks Brace for Rising Credit Risks Amid Iran Conflict 
Warren Buffett and Stephen Curry Charity Dinner Auction Raises $27 Million for Nonprofits 
YouTube and Snap Settle School District Mental Health Lawsuit Ahead of Major Social Media Trial 
SpaceX Shareholders Approve 5-for-1 Stock Split Ahead of Potential IPO 
CRANBURY, N.J., Sept. 22, 2016 -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of therapies for rare and orphan diseases, today announced that John F. Crowley, Chairman and Chief Executive Officer, will participate in a corporate overview and fireside chat at the LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology in New York, NY on September 28, 2016 at 3:05pm ET.
An audio webcast of the presentation can be accessed through the Investors section of the Amicus Therapeutics corporate website at http://ir.amicusrx.com/events.cfm, and will be archived for 90 days.
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq:FOLD) is a global biotechnology company at the forefront of therapies for rare and orphan diseases. The Company has a robust pipeline of advanced therapies for a broad range of human genetic diseases. Amicus’ lead programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease, SD-101 for Epidermolysis Bullosa (EB), as well as novel enzyme replacement therapy (ERT) and biologic products for Fabry disease, Pompe disease, and other rare and devastating diseases.
FOLD–G
CONTACTS: Investors/Media: Amicus Therapeutics Sara Pellegrino Senior Director, Investor Relations [email protected] (609) 662-5044 Media: MWW PR Sean Conley [email protected] (646) 381-9096
